Fairness opinions › Acquirers
Boston Scientific: healthcare acquisitions with fairness opinions
5 public-company targets, 2016-2026, $20B combined enterprise value. The multiples Boston Scientific paid and the banker analyses behind each target board's recommendation.
Deals
5
Median EV / EBITDA paid
62.9x
Median EV / revenue paid
6.34x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2026-01-15 | Penumbra | Boston Scientific | Medical Devices and Supplies | $15B | 57.7x | 10.82x | 9.0%–11.0% | Perella Weinberg Partners |
| 2024-06-18 | Silk Road Medical | Boston Scientific | Medical Devices and Supplies | $1.2B | — | 5.47x | 11.7%–14.5% | BofA Securities |
| 2024-01-08 | Axonics | Boston Scientific | Medical Devices and Supplies | $3.4B | 68.0x | 9.29x | 9.5%–11.0% | J.P. Morgan |
| 2022-11-29 | Apollo Endosurgery | Boston Scientific | Medical Devices and Supplies | $615M | — | 6.34x | 11.8%–12.8% | Piper Sandler |
| 2016-09-27 | EndoChoice Holdings | Boston Scientific | Medical Devices and Supplies | $458M | — | 4.28x | 11.8%–13.8% | Guggenheim Securities |